Sign Up Today and Learn More About Proscia Stock
Invest in or calculate the value of your shares in Proscia or other pre-IPO companies through EquityZen's platform.
Proscia Stock
Proscia develops digital pathology software designed to help laboratories and life sciences organizations manage and analyze pathology data.
About Proscia Stock
Founded
2014
Headquarters
Philadelphia, PA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Proscia Press Mentions
Stay in the know about the latest news on Proscia
HNL Lab's digital pathology platform enables faster results and more
healthcareitnews • Apr 02, 2026
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
biospace • Mar 19, 2026
Proscia Earns Top Performance Score in the US, Sweeping 2026 KLAS Digital Pathology Ratings
biospace • Mar 02, 2026
Proscia Named Global 2026 Best in KLAS for Digital Pathology in Europe 100% of customers interviewed would buy again, citing trust for primary diagnosis at scale and a partnership they can count on
biospace • Feb 04, 2026
AI in Pathology Market Projected to Reach USD 2225.62 Million by 2033 Driven by Increased Computing Power and Cloud Scalability Globally – SNS Insider
globenewswire • Dec 15, 2025
Proscia Management
Leadership team at Proscia
Co-Founder & CEO
David West
Co-founder & CTO
Coleman Stavish
Join now and verify your accreditation status to gain access to:
- Proscia Current Valuation
- Proscia Stock Price
- Proscia Management
- Available deals in Proscia and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Proscia Cap Table and Funding History by Share Class and Liquidity Preferences
- Proscia Revenue and Financials
- Proscia Highlights
- Proscia Business Model
- Proscia Risk Factors
- Proscia Research Report from SACRA Research
Trading Proscia Stock
How to invest in Proscia stock?
Accredited investors can buy pre-IPO stock in companies like Proscia through EquityZen funds. These investments are made available by existing Proscia shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Proscia stock?
Shareholders can sell their Proscia stock through EquityZen's private company marketplace. EquityZen's network includes over 450K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."